Literature DB >> 12865066

Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells.

Jørgen Kjaergaard1, Liaomin Peng, Peter A Cohen, Suyu Shu.   

Abstract

Activated T cells with down-regulated L-selectin expression (L-sel(-)) from tumor-draining lymph nodes represent a potent source of specific immune effectors in adoptive immunotherapy. Using congenic pairs of mice and carboxyfluorescein diacetate succinimidyl ester-labeled L-sel(-) T cells, the current study analyzed in vivo proliferation of transferred cells. In the lung of MCA205 tumor-bearing mice, 6% or 0.3 x 10(6) of the 5 x 10(6) donor cells were identified 24 h after transfer. Vigorous proliferation of donor cells was evident on day 2, reaching a maximum on day 6. The proliferation was tumor-specific and CD4 T cells divided with greater magnitude than CD8 cells. Successful adoptive immunotherapy also required sublethal whole-body irradiation (WBI) of the recipient. WBI exerted its effects on facilitating specific T cell proliferation at the tumor site. Taken together, our results demonstrate that adoptively transferred T cells undergo extensive proliferation in response to the tumor and this response is associated with therapeutic efficacy.

Entities:  

Mesh:

Year:  2003        PMID: 12865066     DOI: 10.1016/s1521-6616(03)00090-1

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  8 in total

1.  A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression.

Authors:  Jorgen Kjaergaard; Stephen Hatfield; Graham Jones; Akio Ohta; Michail Sitkovsky
Journal:  J Immunol       Date:  2018-05-25       Impact factor: 5.422

2.  Immunological mechanisms of the antitumor effects of supplemental oxygenation.

Authors:  Stephen M Hatfield; Jorgen Kjaergaard; Dmitriy Lukashev; Taylor H Schreiber; Bryan Belikoff; Robert Abbott; Shalini Sethumadhavan; Phaethon Philbrook; Kami Ko; Ryan Cannici; Molly Thayer; Scott Rodig; Jeffrey L Kutok; Edwin K Jackson; Barry Karger; Eckhard R Podack; Akio Ohta; Michail V Sitkovsky
Journal:  Sci Transl Med       Date:  2015-03-04       Impact factor: 17.956

3.  Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses.

Authors:  Weiyi Peng; Yang Ye; Brian A Rabinovich; Chengwen Liu; Yanyan Lou; Minying Zhang; Mayra Whittington; Yan Yang; Willem W Overwijk; Gregory Lizée; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2010-10-01       Impact factor: 12.531

4.  Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells.

Authors:  Dominik Rüttinger; Rui Li; Walter J Urba; Bernard A Fox; Hong-Ming Hu
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.

Authors:  Li-Xin Wang; Suyu Shu; Mary L Disis; Gregory E Plautz
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

6.  In vivo cytometry of antigen-specific t cells using 19F MRI.

Authors:  Mangala Srinivas; Michael S Turner; Jelena M Janjic; Penelope A Morel; David H Laidlaw; Eric T Ahrens
Journal:  Magn Reson Med       Date:  2009-09       Impact factor: 4.668

7.  Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.

Authors:  Soraya Zorro Manrique; Ana L Dominguez; Noweeda Mirza; Christopher D Spencer; Judy M Bradley; James H Finke; James J Lee; Larry R Pease; Sandra J Gendler; Peter A Cohen
Journal:  Oncotarget       Date:  2016-07-12

8.  p62-DNA-encoding plasmid reverts tumor grade, changes tumor stroma, and enhances anticancer immunity.

Authors:  Franco M Venanzi; Vladimir Gabai; Francesca Mariotti; Gian Enrico Magi; Cecilia Vullo; Albert A Sufianov; Sergey I Kolesnikov; Alexander Shneider
Journal:  Aging (Albany NY)       Date:  2019-11-21       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.